South Korea Atherosclerosis Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Anti-platelet and Anticoagulants, Cholesterol Lowering Medication, ACE Inhibitors, and Others), By Route of Administration (Oral and Injectable), and South Korea Atherosclerosis Drugs Market Insights, Industry Trend, Forecasts to 2033.

South Korea Atherosclerosis Drugs Market Insights Forecasts to 2033

• The South Korea Atherosclerosis Drugs Market Size is Growing at a CAGR of 3.19% from 2023 to 2033
• The South Korea Atherosclerosis Drugs Market Size is Expected to Reach a Significant Share By 2033

The South Korea Atherosclerosis Drugs Market Size is Anticipated to reach a significant share By 2033, Growing at a CAGR of 3.19% from 2023 to 2033

Market Overview

South Korea atherosclerosis drugs market includes statins, PCSK9 inhibitors, and other drugs designed to manage cholesterol levels, reduce inflammation, and improve heart health.  Atherosclerosis, characterized by plaque buildup in the arteries, is a major contributor to heart attacks, strokes, and other cardiovascular disorders. With a growing focus on preventive healthcare and advancements in medical treatments, the demand for drugs that can manage cholesterol levels, reduce plaque formation, and improve heart health is expanding. Statins, which lower cholesterol, remain the most widely prescribed class of drugs, but newer therapies such as PCSK9 inhibitors are gaining traction for their effectiveness in patients with high cholesterol levels who are not responsive to traditional treatments. Furthermore, lifestyle changes and the rise of awareness about cardiovascular health are contributing to an increased demand for these drugs. The market is also benefiting from the robust healthcare infrastructure in South Korea, which includes advanced medical facilities, a well-established pharmaceutical industry, and government initiatives aimed at improving healthcare access.

Report Coverage

This research report categorizes the market for the South Korea atherosclerosis drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea atherosclerosis drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea atherosclerosis drugs market.

Driving Factors

Increasing prevalence of cardiovascular diseases, including atherosclerosis, due to lifestyle changes such as poor diet, lack of physical activity, and rising obesity rates, is a significant driver. The aging population in South Korea also plays a critical role, as older adults are more susceptible to atherosclerosis and related conditions. Additionally, advances in medical research and pharmaceutical innovation have led to the development of more effective and targeted therapies, further boosting market growth.

Restraining Factors

Market faces challenges related to high treatment costs and the need for continuous research to develop more effective and affordable therapies. Despite these challenges, the South Korea atherosclerosis drugs market is poised for continued growth as demand for cardiovascular treatments intensifies.

Market Segmentation

The South Korea atherosclerosis drugs market share is classified into drug type and route of administration.

• The anti-platelet and anticoagulants segment accounted for the largest revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The South Korea atherosclerosis drugs market is segmented by drug type into anti-platelet and anticoagulants, cholesterol lowering medication, ACE inhibitors, and others. Among these, the anti-platelet and anticoagulants segment accounted for the largest revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period. The segment growth is largely driven by the critical role these drugs play in preventing blood clots, reducing the risk of stroke, and managing other cardiovascular complications associated with atherosclerosis.

• The oral segment accounted for the highest market share in 2023 and is expected to grow at a substantial CAGR during the forecast period.

The South Korea atherosclerosis drugs market is segmented by route of administration into oral and injectable. Among these, the oral segment accounted for the highest market share in 2023 and is expected to grow at a substantial CAGR during the forecast period. The segment growth can be driven by their ease of use, convenience, and patient preference, as they do not require healthcare professionals for administration. Common oral drugs used in the treatment of atherosclerosis include cholesterol-lowering statins, anti-platelet medications like aspirin, and other cardiovascular drugs.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea atherosclerosis drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Bausch Health Companies Inc.
• Novartis AG
• AstraZeneca
• Lupin
• Amgen Inc.
• Sanofi
• Pfizer Inc.
• Johnson & Johnson
• Bayer AG, Viatris Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2024, Arrowhead Pharmaceuticals introduced plozasiran and zodasiran, RNA-based drugs targeting specific proteins to significantly lower triglycerides in patients with mixed hyperlipidemia.

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the South Korea atherosclerosis drugs market based on the below-mentioned segments

South Korea Atherosclerosis Drugs Market, By Drug Type

• Anti-platelet and Anticoagulants
• Cholesterol Lowering Medication
• ACE Inhibitors
• Others

South Korea Atherosclerosis Drugs Market, By Route of Administration

• Oral
• Injectable